London London: Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer is being studied rapidly as an alternative to chemotherapy and radiotherapy. This is because it targets cancer cells directly, and reduces negative effects associated with more traditional treatments.

Tumors, such as some breasts and ovarian cancer, can express markers Her2. Her2 is responsible for the development of cancer and aiming for existing treatments, such as the type of most commonly used antibodies, igg. However, this treatment is not always effective in some patients.

Now, scientists have examined a separate antibody type, IGE, which activates the patient's immune system in different ways compared to IGG. Since they function on individual immune cells for IGG, the IGE antibody stimulates inactive immune cells specifically to directly target cancer cells in the 'micro environment' around the tumor.

In a study conducted by Dr. Heather Bax at King's College London, the team prepared the IGE versions of existing IGG remedies and tested their ability to activate immune cells against Her2-Expressing Cancer cells.

The IGE was shown to direct immune cells against Her2-Expressing Cancer cells and slow down the development of tumors in mice. Tumors developed in mice are considered resistant to traditional remedies, showing that this new treatment can be an option for patients who do not react to existing treatments.

Further investigation revealed that the IGE Antibody stimulated and re-programmed the 'immune microinavarnament' around the tumor, which turned into an immunospressive immunostimulator reaction. This means that the immune system was activated to target cancer cells and overcome tumor actions to suppress the attack.

The study has shown the ability of IGE as a new therapy for Her2-Expressing Cancer, including cancer resistant to other treatments. Researchers believe that with correct investment and development, this method can be used in humans in 3-5 years. Postdorator Research Fellow at St. John's Institute of Dermatology at King's College London, senior writer Dr. Heather Bax said, “About 20% of the breasts and ovarian cancer markers express, Her2. By generating anti-Her2 igs antibodies equal to the Igs used, we show that the first time we show that igs representatives by generating anti-her2 igs. Use the unique mechanisms to re-program microenewarnament, switch immune cells effectively to target Her2-expresses cancer, including cancer resistant to existing treatments.

“Our findings indicate that IGE Antibody can provide a possible new treatment option for Her2-express cancer.”

Professor Sophia Karagianis, Professor of Translational Cancer Immunology and Immunotherapy at St. John's Institute of Dermatology, King's College London, said, “By creating a panel of IGE antibodies and studying them in various tumor types, we consistently found that human immune system reacts to prevent cancer.

“The findings of our latest studies talk about the ability to implement IGE to stimulate effective responses against hard-to-treatment solid tumors. This new class of drugs is likely to benefit various patient groups in this new class and open a new front in the fight against cancer.”